Drugs /

r-da-epoch regimen

Back to Drugs List

Overview

NCI Definition [1]:
A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of non-Hodgkin lymphoma (NHL).

Clinical Trials

View Clinical Trials for r-da-epoch regimen

R-da-epoch regimen has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating r-da-epoch regimen, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open).

HHV8 Positive and MS4A1 Expression are the most frequent biomarker inclusion criteria for r-da-epoch regimen clinical trials.

Diffuse large B-cell lymphoma, mediastinal B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, and primary mediastinal B-cell lymphoma are the most common diseases being investigated in r-da-epoch regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating R-Da-Epoch Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating r-da-epoch regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dose-adjusted epoch-r regimen, da-epoch-r
NCIT ID [1]:
C140097

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.